Sandostatin Lar 20 mg

Sandostatin LAR 20 mg is a sustained-release octreotide acetate powder for suspension, used for managing symptoms of certain conditions. This intramuscular injection is designed for long-term use and is manufactured by Novartis Pharmaceuticals Canada Inc.

Sandostatin LAR 20 mg is primarily used to manage symptoms associated with conditions like acromegaly and certain gastrointestinal disorders. Octreotide acetate, the active ingredient, helps control excessive hormone production and reduce symptoms such as diarrhea and flushing. This medication is often prescribed for long-term symptom management and is administered via intramuscular injection.

Common effects of Sandostatin LAR 20 mg may include injection site reactions, nausea, and abdominal pain. Some users may experience changes in blood sugar levels or gallbladder issues. These effects can vary and are not exhaustive; individual experiences may differ.

Sandostatin LAR 20 mg should be handled with care, ensuring proper storage and administration by healthcare professionals. It is important to discuss any existing medical conditions or medications with a healthcare provider before use. This medication is not suitable for everyone, and precautions should be taken to avoid potential complications.

Sandostatin LAR 20 mg may interact with certain medications, including those metabolized by the liver. It is important to inform healthcare providers about all current medications to avoid potential interactions. Alcohol and other substances may also affect the efficacy or safety of this medication.